👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

UCB SA ADR (UCBJY)

OTC Markets
Currency in USD
94.14
-0.49(-0.51%)
Delayed Data
UCBJY Scorecard
Full Analysis
Has raised its dividend for 15 consecutive years
Trading near 52-week High
Fair Value
Day's Range
94.1495.17
52 wk Range
34.8595.17
Prev. Close
94.62
Open
94.39
Day's Range
94.14-95.17
52 wk Range
34.85-95.17
Volume
5,668
Average Volume (3m)
15,640
1-Year Change
124.32%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
UCBJY Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
79.90
Downside
-15.13%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

UCB SA ADR Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; minzasolmin and UCB0222 for Parkinson’s disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Employees
8767

Compare UCBJY to Peers and Sector

Metrics to compare
UCBJY
Peers
Sector
Relationship
P/E Ratio
137.4x27.6x−0.6x
PEG Ratio
−5.01−0.630.00
Price/Book
3.7x4.1x2.6x
Price / LTM Sales
6.0x2.6x3.2x
Upside (Analyst Target)
−7.9%26.3%47.1%
Fair Value Upside
Unlock8.6%7.1%Unlock

People Also Watch

520.59
SNPS
-4.56%
34.030
MKKGY
-1.29%
76.72
JCI
-1.24%
338.57
ETN
-2.04%
47.32
SMCI
-0.15%

FAQ

What Is the UCB ADR (UCBJY) Stock Price Today?

The UCB ADR stock price today is 94.14

What Stock Exchange Does UCB ADR Trade On?

UCB ADR is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for UCB ADR?

The stock symbol for UCB ADR is "UCBJY."

Does UCB ADR Pay Dividends? What’s The Current Dividend Yield?

The dividend yield is 0.49%.

What Is the UCB ADR Market Cap?

As of today, UCB ADR market cap is 35.93B.

What is UCB ADR Earnings Per Share?

The UCB ADR EPS is 1.26.

What Is the Next UCB ADR Earnings Date?

UCB ADR will release its next earnings report on Oct 28, 2024.

From a Technical Analysis Perspective, Is UCBJY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.